Substance-related disorders

Disease4 papers1 finding

Humans4

Associations

1

Semaglutide

downin humans1Low certainty

1 study

Semaglutide lowers the risk of substance-related disorders in humans.
Humanshigher attained dose vs lower dose2 years
Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss · npj metabolic health and disease · 1 Sep 2026

Semaglutide →

Trial sponsors

Albert Einstein College of Medicine
1 trialPhase 4112 people
Johns Hopkins University
1 trialPhase 4104 people
National Institute on Drug Abuse
2 trialsPhase 2130 people
Milton S. Hershey Medical Center
1 trialPhase 2200 people
University of Maryland Baltimore
1 trialPhase 1142 people
University of Washington
1 trialPhase 120 people
University Hospital, Basel, Switzerland
1 trialPhase 116 people

Latest

4

bioRxivHumansPreprint24 Sep

EEG Functional Connectivity Reveals Accelerated Brain Aging in Young Adults with Cognitive Deficits and Mental Health Conditions

NeurologyHumans23 Sep

Stroke in the Young: Incidence, 30-Day Case Fatality Rates, and Risk Factors Over Time in a Population-Based Study

JRSM Cardiovascular DiseaseHumans3 Sep

Premature mortality from acute myocardial infarction and psychoactive substance use in the United States: An observational trend (1999-2023) and forecasting (2035) study

npj Metabolic Health and DiseaseHumans2 Sep

Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss